Money moves in silence. Download 2025 State of Venture Report: a data-driven analysis of active funds, unicorn, and family offices
About usSign in

Forbion Capital Partners

Status
ACTIVE
Global HQ
Naarden, Netherlands
Countries of investment
  • United States
  • United Kingdom
  • Netherlands
  • Germany
  • Switzerland
  • Italy
  • France
  • Canada
  • Belgium
Investment stages
  • Series A
  • Series B
  • Series C
  • Growth
Industries
  • Biotech
  • Life Sciences
  • TechBio
  • Therapeutics
About
A leading European biotech investor focused on therapeutics, drug discovery, and breakthrough life-science technologies. Forbion supports long-term R&D and commercialization processes.
Min check size
$10.6M
Max check size
$31.8M
Fund size
NPS

Investment Thesis

Forbion invests in biotech, life sciences, and therapeutic innovation—backing companies developing novel drugs, platforms, and medical treatments with global clinical potential.
Lead investor
Co Invest
Number of exits
Preferred contact method

Manager's Experience

Managed by life science and biotech experts with years of experience in therapeutics, ag-science, and healthtech investments. Their backgrounds include scientific research, portfolio management, and company-building in bio innovation.

Forbion Capital Partners Contacts Information

Primary contact

Secondary contact

Team

Dirk Kersten – Managing Partner

Geert-Jan Mulder – Managing Partner

Sander Slootweg – Managing Partner

Martien van Osch – Managing Partner

Nanna Lüneborg – General Partner

Marco Boorsma – General Partner

Jasper Bos – General Partner

Alexander Hoffmann – General Partner

Dmitrij Hristodorov – General Partner

Wouter Joustra – General Partner

Rogier Rooswinkel – General Partner

Robbert van de Griend – General Partner (IR & Impact)

Jon Edwards – Partner

Joy Faucher – General Partner

Mathias Vinther – Partner

Audrey Cacaly – Principal

Vanessa Carle – Principal

Morgan Haller – Principal

Tim Lohoff – Principal

Regina Salvat – Principal

Carolin Lanfer – Senior Associate

Marc-Olivier Turgeon – Senior Associate

Melanie de Almeida – Associate

Kanay Khakhria – Associate

Maximillien Souvereyns – Associate

Gilles van Tienderen – Associate

Felix Güttersberger – Analyst

Vincent Loon – Business Analyst

Cerelia Caesar – Fellow

Luuk de Vries – Analyst

Roberto Hofmann – Analyst

Joseph Iwasyk – Analyst

Nat Kolber – Fellow

Charlotte Koldeweij – Analyst

Vivien Veninga – Fellow

Per Falholt – Operating Partner

Rory Gummerson – Operating Partner & Talent Acquisition

Peter Høngaard Andersen – Operating Partner

Carlo Incerti – Operating Partner

John J.P. Kastelein – Operating Partner

Ton Logtenberg – Venture Partner

John Montana – Operating Partner

Gijs van den Brink – Operating Partner

Sander van Deventer – Operating Partner

Philip Astley-Sparke – Venture Partner

Josh Brumm – Venture Partner

Matt Cooper – Venture Partner

Cees de Jong – Venture Partner

Michael Hayden – Venture Partner

Jonathan McNeill – Venture Partner

Yigal M. Pinto – Venture Partner

Patrick Round – Venture Partner

Onno van de Stolpe – Venture Partner

Patrick Vink – Venture Partner

Jens Wendland – Venture Partner

Simon J. Clark – Advisor

John Ford – Advisor

Scott Friedman – Advisor

Frank G. Holz – Advisor

Stefan Oschmann – Advisor

Holger Reithinger – Senior Advisor

Steen Riisgaard – Advisor

Liz Rodgers – Advisor

Floor Saris – Advisor

Feike Sijbesma – Senior Advisor

Laura Asbjornsen – Head of Marketing & Communications

Silva Dezelan – Head of Impact and ESG

Jennifer Fritzsche – Vice President Finance

Cyril Lesser – Vice President Finance (Funds)

Marc van Voorst tot Voorst – Head of Public Affairs

Elisa Camorani – Senior Associate ESG & Impact

Stijn Jochemsen – Finance Manager

Sabina Osenberg – Junior Fund Controller

Walter Schram – Finance Manager

Devan Sequeira – IT Solution Architect

Pascal van Wees – Finance Manager

Iris Veldman – Deal Counsel

Patricia Vonk – AML/KYC Manager

Maureen Wouters – Paralegal

Danielle de Magalhães – Executive Assistant

Sharon Dirkse – Office Manager

Alicia Dortona – Office Manager

Dragana Dragusin – Executive Assistant

Tineke Duijn – Office Assistant

Marijana Stojanovic – Receptionist

Chelle Tjabring – Senior Executive Assistant

Olga Ziessen – Manager Secretarial Services

Francine MacLeod – HR Administrator

Portfolio

AAVantgarde Bio

AIRNA

AM-Pharma

Amphista Therapeutics

Anaveon

Azafaros

Beacon Therapeutics

Bicycle Therapeutics

BioInvent

Braveheart Bio

Calluna Pharma

CatalYm

CellCentric

Citryll

Complement Therapeutics

Dyne Therapeutics

eeden

Elevara Medicines

enGene

Engrail Therapeutics

Enterprise Therapeutics

Expedition Therapeutics

F2G

Gate Bioscience

Genomines

Granite Bio

Kynexis

LoQus23 Therapeutics

MapLight Therapeutics

Marea Therapeutics

Mestag Therapeutics

Mosanna Therapeutics

Navigator Medicines

NeRRe Therapeutics

NewAmsterdam Pharma

Noema Pharma

NorthSea Therapeutics

Novameat

Numab

OMEICOS Therapeutics

Orbis Medicines

PACT

Pheon Therapeutics

Precirix

Prilenia Therapeutics

Progentos Therapeutics

Protego

Purespring Therapeutics

Rectify Pharma

Replimune

RyCarma

Seamless Therapeutics

Solasta Bio

Sparrow

SynOx Therapeutics

Tessellate Bio

VectorY

Verdiva Bio

Vor Bio

Fund number
Vintage Year
Net Internal Rate of Return
Investment Multiple
Capital Allocation
Management Fee
Carried Interest
AUM
Follow-on Investments
Graduation Rate
Write-Off Ratio
Last profile update timestamp